What makes Primo raws harder to source clean compared to Deca or NPP?

Primo synthesis complex, fewer legitimate pharmaceutical sources exist

Raw availability limited, demand far exceeds clean supply.

Primo expensive to produce, cutting corners tempting.

Deca and NPP mass-produced; Primo never widely commercialized.

Primo raws often substituted or heavily underdosed.

Complex esterification increases impurity risk during synthesis

Fewer labs capable of producing true methenolone.

Primo lacks veterinary demand supporting large-scale manufacturing.

High cost incentivizes fakes more than Deca

Deca synthesis simpler, supply chain well-established globally

Primo requires precise chemistry, harder to replicate cleanly.

Limited pharma history means fewer reference standards

Underground labs struggle sourcing pharmaceutical-grade Primo raws.

NPP piggybacks nandrolone supply, Primo stands alone.

Primo raws often recycled or mislabeled compounds.

Lower yields make clean production economically unattractive.

Primo popularity surged faster than raw production capacity.

Deca benefits from decades-old industrial synthesis pathways

Primo raws attract adulteration due to premium pricing.

Clean Primo exists, but sourcing reliably is difficult.